B of A Securities has upgraded Bristol-Myers Squibb Co (BMY) to Buy from Neutral, reflecting a more optimistic outlook on the pharmaceutical giant's prospects. The upgrade, effective December 14, 2025, coincides with the company's current stock price of $54.11.
Bristol-Myers Squibb, headquartered in Princeton, New Jersey, specializes in the discovery, development, and sale of biopharmaceutical products. The company employs approximately 34,100 full-time staff and is known for its extensive portfolio, which includes key products like Opdivo, Eliquis, and Revlimid. As of December 11, 2025, Bristol-Myers Squibb boasts a market capitalization of $104.1 billion and a P/E ratio of 17.24, with an EPS of 2.96 and a dividend yield of 492.1%.
The upgrade signals a shift in analyst sentiment, possibly due to improved fundamentals or enhanced confidence in the company’s strategic direction. Market participants often view analyst ratings as valuable insights, although they should consider a range of factors—including company fundamentals and industry trends—when making investment decisions.
Upcoming earnings are anticipated on October 29, 2026, with an estimated EPS of $1.49 and revenue of $11.2 billion, following a strong Q3 performance where the company reported EPS of $1.63, surpassing estimates by 6.9%. Analyst consensus currently stands at 4 Strong Buy, 7 Buy, 21 Hold, and 2 Sell, suggesting a general expectation of stability in the company's performance moving forward.
This update provides insight into the evolving analyst perspectives on Bristol-Myers Squibb, which may influence investor sentiment as new information becomes available.